Autolus Therapeutics plc (NASDAQ:AUTL)
| Market Cap | $241.65M-26.8% |
| Revenue (ttm) | $137.40M+168.7% |
| Net Income | -$256.00M-13.9% |
| EPS | -$0.97-15.5% |
| Shares Out | 266.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,898,442 |
| Open | $0.96 |
| Previous Close | $0.98 |
| Day's Range | $0.90 - $0.98 |
| 52-Week Range | $0.90 - $2.58 |
| Beta | 2.35 |
| Analysts | Buy |
| Price Target | $8.87(+877.63%) |
| Earnings Date | Mar 10, 2027 |
About AUTL
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 10, 2027Earnings report
$AUTL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AUTL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AUTL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AUTL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AUTL Revenue by Segment or Geography
| Product revenue, net | $41.24M | 99.76% |
| Other income, net | $99.00K | 0.24% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AUTL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AUTL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AUTL
| IBBiShares Biotechnology ETF | $1.21M |
| MOONDirexion Moonshot Innovators ETF | $394.92K |
| GWXState Street SPDR S&P International Small Cap ETF | $102.87K |
| QQQSInvesco NASDAQ Future Gen 200 ETF | $50.45K |
| APIEActivePassive International Equity ETF | $28.82K |
| IBBQInvesco Nasdaq Biotechnology ETF | $16.46K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from AUTL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Commercial progress evident with AUCATZYL revenue generation and positive clinical data from CARLYSLE trial supporting therapeutic validation.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 4Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| MOON | Direxion Moonshot Innovators ETF | 2.00% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.30% |
| CANC | Tema Oncology ETF | 0.16% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
| IBB | iShares Biotechnology ETF | 0.01% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
| APIE | ActivePassive International Equity ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
